Trials / Conditions / Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

10 registered clinical trials studyying Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma NCT07042438	City of Hope Medical Center	Phase 2
Recruiting	Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chime NCT06854159	Joseph Tuscano	Phase 2
Recruiting	Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for NCT06905509	Joseph Tuscano	Phase 2
Terminated	Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19 NCT06343376	Roswell Park Cancer Institute	Phase 1
Recruiting	Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patien NCT05821088	David Bond, MD	Phase 2
Withdrawn	Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Rec NCT05228249	Fred Hutchinson Cancer Center	Phase 1
Completed	Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma NCT04432506	M.D. Anderson Cancer Center	Phase 2
Unknown	Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated Wit NCT04870853	M.D. Anderson Cancer Center	—
Terminated	Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients Wit NCT04205838	Jonsson Comprehensive Cancer Center	Phase 2
Completed	Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin NCT03210662	M.D. Anderson Cancer Center	Phase 2